Home › Compare › YGYIP vs ABBV
YGYIP yields 1000.00% · ABBV yields 3.06%● Live data
📍 YGYIP pulled ahead of the other in Year 1
Combined, YGYIP + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YGYIP + ABBV for your $10,000?
Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. It operates in three segments: Direct Selling, Commercial Coffee, and Commercial Hemp. The company offers nutritional supplements, gourmet coffee, weight management products, skincare and cosmetics, health and wellness, packaged foods, lifestyle products, pet care, digital products, telecare health services, apparel and fashion accessories, and business lending products. It also produces and sells coffee products under the Café La Rica, Café Alma, Josie's Java House, Javalution Urban Grind, Javalution Daily Grind, and Javalution Royal Roast brands; and produces and markets a line of coffees under the JavaFit brand directly to consumers. In addition, it offers CBD oils from hemp stock. The company sells coffee and equipment to wellness and retirement communities, and various cruise lines and coffee service operators, as well as through distribution network. Youngevity International, Inc. also markets its products through a range of consumer Websites, such as youngevity.com; ygyi.com; heritagemakers.com; hempfx.com; clrroasters.com; cafelarica.com; javalution.com. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013. Youngevity International, Inc. was founded in 1996 and is headquartered in Chula Vista, California.
Full YGYIP Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.